You are here: Industry Insights > ovarian cancer

News List

Anixa Biosciences, Moffitt Cancer Center File IND Application for Ovarian Cancer CAR-T Therapy americanpharmaceuticalreview
March 25, 2021
Anixa Biosciences announced an IND (Investigational New Drug) application for its ovarian cancer CAR-T (Chimeric Antigen Receptor T-cell) therapy has been filed with the U.S. Food and Drug Administration (FDA).
NICE approves Lynparza plus Avastin via Cancer Drugs Fund pharmatimes
March 19, 2021
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca/MSD’s Lynparza combined with Roche’s Avastin for certain patients with ovarian cancer via the Cancer Drugs Fund (CDF).
Kazia Licenses Cantrixil, a Clinical-stage, First-in-class Ovarian Cancer Drug Candidate, to Oasmia Pharmacetical AB prnasia
March 02, 2021
Kazia Therapeutics Limited, an Australian oncology-focused biotechnology company, is pleased to announce that it has entered into an exclusive worldwide license agreement with Oasmia Pharmaceutical AB (STO: OASM).
Data Safety Monitoring Committee Green Lights Ovarian Cancer Study americanpharmaceuticalreview
February 24, 2021
VBL Therapeutics announced the results of the independent Data Safety Monitoring Committee (DSMC) pre-planned review of the ongoing OVAL Phase 3 registration enabling study of VB-111 in recurrent ovarian cancer.
BioVaxys and BioElpida Sign Term Sheet for Clinical Grade BVX-0918A Bio-production prnasia
February 19, 2021
BioVaxys Technology Corp. announced that it has signed a Term Sheet with BioElpida S.A.S. of Lyon, France, to collaborate on the build-out for the clinical-grade manufacturing process and aseptic packaging for BXV-0918A, BioVaxys' vaccine for Stage ...
NICE backs GSK’s Zejula in advanced ovarian cancer pharmatimes
January 18, 2021
The UK’s National Institute for Health and Care Excellence (NICE) has recommended the use of GlaxoSmithKline’s Zejula (niraparib) on the NHS for women with newly diagnosed advanced ovarian cancer.
AIVITA Biomedical Closes $25 Million Financing Round prnewswire
December 30, 2020
AIVITA Biomedical, Inc., a private biotechnology company developing personalized vaccines for the treatment of cancer and prevention of COVID-19, has closed its Series B-2 financing round for up to $25 million. Financing was provided by several life ...
LYNPARZA (olaparib) get three new approvals in Japan expresspharma
December 29, 2020
Approvals in three types of cancer are based on the PAOLA-1, PROfound and POLO Phase 3 Trials.
Sutro Biopharma Announces Interim Data on STRO-002 Study for Ovarian Cancer americanpharmaceuticalreview
December 24, 2020
Sutro Biopharma has provided a clinical update from the company's ongoing dose-escalation Phase 1 study of STRO-002, a folate receptor alpha (FolRα) targeting antibody-drug conjugate (ADC), for patients with ovarian cancer.
Top-line Final Data from Cantrixil Phase I Study Confirms Prior Positive Efficacy and Safety Signals prnasia
December 09, 2020
Kazia Therapeutics Limited, an Australian oncology-focused biotechnology company, is pleased to share top-line final data from its phase I study of Cantrixil (TRX-E-002-1) in patients with persistent or recurrent ovarian cancer (NCT02903771).

Previous page 1 2 3 4 5 6 7 8 Next page